

Commercial Medicines Unit

Commercial in Confidence

NHS Framework Agreement for the supply of products for the treatment of bleeding disorders

Contract Reference Number CM/PHS/15/5499

Period of Framework: 1 July 2018 to 30 June 2019 with options to extend up to a further 36 months. Total maximum framework agreement period including extensions will be no more than 48 months

Framework currently extended until 30 June 2022.

Briefing Note – June 2018

Please be aware that information contained within this briefing note is commercial in confidence and for use by participating trusts only. This briefing note must not be distributed outside of the NHS.

Version 11 March 2021

Document revision control

Version	Author/editor	Notes	Date published
V1.0	Wendy Roach	1st edition	25 June 2018
V2.0	Wendy Roach	Supplier of Ceprotin amended from Baxalta to Shire Pharmaceuticals Amendment of Voncento price	04 July 2018
V3.0	Wendy Roach	Participating Authorities spreadsheet has been updated in-line with new Home Delivery Framework Agreement CM/MSR/15/5480	January 2019
V4.0	Wendy Roach	Not relevant	Not relevant
V5.0	Wendy Roach	1. Framework agreement has been extended for seven months from the 30 June 2019, new expiry date is 31 January 2020 2. Price of Alphanate has been amended to 0.09p/IU from 0.33p/IU	June 2019
V6.0	Wendy Roach	Price change to Emicizumab from £33.00/Mg to £19.48/Mg	August 2019
V7.0	Wendy Roach	Framework Agreement has been extended by 5 months from 31 January 2020. New expiry date is 30 June 2020 CMU contact details updated Haemoctin is now only available in 1000IU vials Not relevant	December 2019



V8.0	Karen Bell	Alphanine has been withdrawn from the framework. A 2500iu size of Feiba has been added to the framework.	March 2020
		71-2110 0-20 011 0-20 011 0-20 011 0-20 010 0-20 010 010 010 010 010 010 010 010 010 0	
V9.0	Karen Bell	Price change to Coagadex from £2.90/IU to £1.70/IU	April 2020
V10.1	Karen Bell	V10.0 - Framework extended until 30 June 2021 for all products with exception of all PD Factor VIII products (Haemoctin®, Fanhdi®, Octanate LV®, Optivate) and the Emicizumab (humanised bispecific antibody) product Hemlibra®. These products are now available via the Haemophilia A products framework CM/PHS/17/5564, which goes live on 1 July 2020. This extension has no changes to prices. V10.1 – error on end date corrected in document.	May 2020
V11.0	Karen Bell	Framework extended until 30 June 2022 for all products on the previous extension with the exception of Alphanate from Grifols which will be withdrawn as of 30 June 2021. All prices remain the same, apart from an increase in price on Voncento from CSL which is now £0.24 per unit as opposed to £0.2250 per unit. Biotest require a lead-time of 8-12 weeks for stock delivery to any new patients prescribed Haemonine.	March 2021



Background

The Commercial Medicines Unit (CMU) has awarded a national framework agreement for the supply of products for the treatment of bleeding disorders. The framework is to be used by NHS trusts in England, Scotland, Wales and Northern Ireland predominantly in hospitals but also in patients' homes.

The framework agreement will commence on 1 July 2018 and is for a 12 month period with options to extend for up to a further 36 months. The total maximum framework period including any extensions will be no more than 48 months. Following a twelve month extension the framework will now expire on the 30 June 2021.

Products awarded onto the framework are:

- Recombinant Factor VIIa
- Plasma Derived Factor VIII
- Plasma Derived Von Willebrand concentrate
- Plasma Derived Factor VIII Inhibitor Bypassing Fraction
- Plasma Derived Factor IX
- Plasma Derived Factor XIII concentrate
- Plasma Derived Protein C Concentrate
- Plasma Derived Fibrinogen concentrate
- Fresh Frozen Plasma
- Plasma Derived FX concentrate
- Recombinant Porcine Factor VIII concentrate
- Plasma Derived Prothrombin Complex Concentrate
- Emicizumab (humanised bispecific antibody)

Scope of the framework

This framework will supersede the following CMU framework agreements all of which will expire on the 30th June 2018:

CM/PHS/11/5263 - Blood Clotting Factors excl. rFVIII and rFIX

CM/PHS/13/5417 - Prothrombin Complex Concentrate

CM/PHS/16/5502 - Factor X and Porcine Factor VIII

Products on this new framework where applicable will be supplied complete with diluents and devices for administration in a variety of vial sizes.

The award of this framework was based on the most economically advantageous tender (MEAT). The award criteria were as follows:

Criteria	Weighting
Eligibility	Pass / Fail
Price	85%
Security of Supply	10%
Number of vials/syringes available	5%



Framework Award

The award of the framework is as follows:

Product	Supplier	Brand Name	Vial/Syringe Sizes	Rank	Framework Price (£) per Uol	Manufacturer Part Number	Annual Volume Available per UOI	Needle Free Device
Recombinant Factor VIIa	Novo Nordisk Ltd	NovoSeven®	1mg 2mg 5mg 8mg	n/a	459.55	7198779 7198787 7198795 7198809	200,000	No
PD Factor VIII	PD Factor VIII products are not available on this framework after 30 June 2020. From 1 July 2020 they can be found on the Haemophilia Framework ref: CM/PHS/17/5564		54					
	CSL Behring UK Ltd	Voncento®	1200iu 2400iu	1		A8501 A8466	15,889,500	Yes
PD Factor VWF	Grifols UK Ltd	Alphanate®	500iu 1000iu 2000iu	2	*See Appendix 1	n/a	15,000,000	Yes
	Octapharma Ltd	Wilate®	500iu 1000iu	3		n/a n/a	23,200,000	Yes



	LFB Biomedicaments	WILLFACT®	1000iu	4		USP0262	1,950,000	Yes
PD Factor VIII Inhibitor Bypassing Fraction	Shire Pharmaceuticals Ltd	FEIBA®	500iu 1000iu 2500iu	n/a	Not relevant	1502624 1502625 1502887	Not relevant	Yes
DD Footon IV	Biotest (UK) Ltd	Haemonine®****	500iu 1000iu	1	0.26	n/a n/a	480,000	No
PD Factor IX	Bio Products Laboratory Ltd	Replenine®	500iu 1000iu	2	0.28	7579 7503	5,360,000	Yes
PD Factor XIII	CSL Behring UK Ltd	Fibrogammin®	250iu 1250iu	n/a	0.43	E5835 F5788	800,000	Yes
PD Protein C Concentrate	Shire Pharmaceuticals Ltd	Ceprotin®	500iu 1000iu	n/a	Not rel evant	E6005030112001 E6008130112001	Not relevant	No
PD Fibrinogen	CSL Behring UK Ltd	Riastap®	1g`	1	299.00	A2176	15,000	
Concentrate	LFB Biomedicaments	FibCLOT®	1.5g	2	525.00	USP1713	4,000	Yes
Fresh Frozen Plasma	Octapharma Ltd	OctaplasLG A OctaplasLG B OctaplasLG O OctaplasLG AB	200mL 200mL 200mL 200mL	n/a	63.75	n/a n/a n/a n/a	96,000	n/a
PD Factor X	Bio Products Laboratory Ltd	Coagadex®	250iu 500iu	n/a	1.70****	901030 901031	410,000	Yes



Recombinant Porcine Factor VIII	Shire Pharmaceuticals Ltd	Obizur®	500iu	n/a	Not relevant	1504831	Not relevant	No
	Shire Pharmaceuticals Ltd	Prothromplex®	600iu	1	Not relevant	1505967	Not relevant	No
PD Prothrombin Complex Concentrate	Octapharma Ltd	Octaplex®	500iu 1000iu	2	0.25	n/a n/a	36,000,000	Yes
Concentrate	CSL Behring UK Ltd	Beriplex®	250iu 500iu 1000iu	3	0.25	OBMN275300 OBMN515300 C1642	16,000,000	Yes
Emicizumab (humanised bispecific antibody)	Emicizumab is not available on this framework after 30 June 2020. From 1 July 2020 it can be found on the Haemophilia Framework ref: CM/PHS/17/5564							

^{*}Increased volume from 1,800,000 to 36,000,000

^{**}New price from August 2019

^{***}New price from February 2020

^{****}New price from April 2020

^{****} Biotest require a lead-time of 8-12 weeks for stock delivery to any new patients prescribed Haemonine.



*Further information on Von Willebrand Factor including prices can be found in Appendix 1.

Price Review

Prices for all products will be fixed for 12 months accept for the three product listed below, where prices will be fixed for a 6 month period. Prices may be reviewed following the price fixed periods.

Product
Recombinant Factor VIIa
PD Factor VIII Inhibitor Bypassing Fraction
Emicizumab (humanised bispecific antibody)

Minimum Expected Requirements of the Awarded Suppliers

Below are the minimum required service levels suppliers are expected to meet:

With effect from the commencement of the framework, the supplier must maintain a level of stock holding sufficient to meet 12 weeks' anticipated demand. The CMU will monitor monthly volumes and adjust the required stock holding figure in line with actual volumes. Any amends will be done on a quarterly basis and in conjunction with the supplier.

Where any products are supplied under this framework the period of time between the date of supply of these goods to the Participating Authority and the expiry date shown on the goods ("the shelf life") shall be not less than 12 months.

Supply of any product with a shelf life less than 12 months must be agreed with the Participating Authority prior to delivery.

In the event that the Supplier supplies product with a shelf life of less than 12 months (or such other period as the Participating Authority must have agreed), the Supplier shall, upon request by the Participating Authority and at no cost to the Participating Authority, replace any product the Participating Authority is unable to use within the product's remaining shelf life period, any replacement product must have a shelf life greater than 12 months. Alternatively, CMU shall be entitled to terminate this framework agreement with immediate effect on giving written notice to the Supplier.

The Supplier shall be responsible for ensuring security of delivery to the appropriate delivery point.

No delivery charges for standard deliveries will be accepted within this framework agreement.

The Supplier will deliver to third party homecare suppliers on current and any future national framework agreements for the home delivery of clotting factor products.

The Supplier must give notification to CMU within 24 hours if the stock holding drops below 12 weeks average sales.

The Supplier must give notification to CMU within 4 hours if the stock holding drops below eight weeks average sales.

If stock levels fall below the required minimum level, suppliers are expected to take action to rectify the issue; failure to do so may lead to termination of the framework agreement with the supplier.

Where a Supplier is unable to meet the delivery requirements of locally agreed contractual arrangements, the supplier shall be liable for any incurred or additional costs incurred by the customer resulting from the requirement to source suitable product from an alternative supplier.

In the event of the goods being recalled, initiated by the manufacturer of the goods, the Secretary of State for Health or MHRA (or any such similar regulatory body), the Supplier shall, without delay and at its own expense, arrange for the collection of such goods and credit the Participating Authority for any goods delivered but unused by the Participating Authority including part used packs.



Conditions of Contract

The NHS conditions of contract for the purchase of goods and NHS supplementary conditions of contract for the purchase of pharmaceuticals were used within the ITT. Copies of these documents are available from CMU.

Participating Trusts

A list of all participating authorities can be found below:



Third party homecare suppliers (as appointed by trusts) will also have access to the contract pricing.

Supplier Information

Supplier specific information trusts may find useful can be found in the following appendices:

- Appendix 2 Bio Products Laboratory Ltd
- Appendix 3 Biotest (UK) Ltd
- Appendix 4 CSL Behring UK Ltd
- Appendix 5 Grifols UK Ltd
- Appendix 6 LFB BIOMEDICAMENTS
- Appendix 7 Novo Nordisk Ltd
- Appendix 8 Octapharma Ltd
- Appendix 9 Roche Products Ltd
- Appendix 10 Shire Pharmaceuticals Ltd

CMU Contact Details

For further information regarding this framework, please contact:

Karen Bell
Senior Operations Advisor and Commercial Practitioner
Mob: GRO-C
karen.bell7@ GRO-C

Wendy Roach
Senior Operations Manager and Commercial Lead
Tel: 0113 GRO-C
Mob: GRO-C
wendy.roach@ GRO-C

CMU would like to thank the UKHCDO, NHS England, and the CRG for Blood Disorders, the Haemophilia Nurse's Association, the Haemophilia Society and colleagues from Scotland, Wales and Northern Ireland for their participation in this procurement process.



Appendix 1 – Von Willebrand Factor

Von Willebrand Factor and Factor VIII ratios

Product	Supplier	Brand Name	Ratio FVIII/vWF	Price per FVIII and vWF
	CSL Behring	Voncento	VWF 1200iu, 2400iu VIII 500iu, 1000iu	0.24 £/iu** 0.58 £/iu**
DD Footor VAVE	Grifols	Alphanate*	VWF-1200iu VIII-1000iu	0.09 £/iu
PD Factor VWF	Octapharma	Wilate	VWF 500iu, 1000iu VIII 500iu, 1000iu	0.32 £/iu 0.32 £/iu
	LFB Biomedicaments	WILLFACT	VWF 1000iu	0.85 £/iu

^{*}product withdrawn from framework 30 June 2021.
** new price as of 1 July 2021.



Von Willebrand Factor - vial prices

NPC	NPC Description	PCK	Supplier	Price
DBU036	FACTOR VIII/VON WILLEBRAND (VONCENTO) FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 500UNIT/1,200UNIT	1	CSL Behring UK Ltd	£288.00**
DZR036	FACTOR VIII/VON WILLEBRAND (VONCENTO) FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 1000UNIT/2,400UNIT	1	CSL Behring UK Ltd	£576.00**
DBK070	FACTOR VIII/VON WILLEBRAND FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 1000UNIT	1	Grifols UK	£90.00
DBK071	FACTOR VIII/VON WILLEBRAND FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 500UNIT	1	Octapharma Ltd	£160.00
DBK070	FACTOR VIII/VON WILLEBRAND FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 1000UNIT	1	Octapharma Ltd	£320.00
DBK070	FACTOR VIII/VON WILLEBRAND FACTOR POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VIAL 1000UNIT	1	LFB Biomedicaments	£850.00

^{**} new price as of 1 July 2021.



Appendix 2 – Bio Products Laboratory Ltd

Address for	Sales Order Contact	Customer Service Department
purchase orders	1st Line Address	Dagger Lane
	2nd Line Address	Elstree , Hertfordshire
	Postcode	WD6 3BX
	Telephone	0208 957 2251
	Fax	01444 447403
	Email	orders@bpl.co.uk
Accounts Contact	Name	Annie Snell
	Telephone	0208 957 GRO-C
	Email	annie.snell@ GRO-C
Sales Director	Name	David Lewis
Contact	Telephone	GRO-C
	Email	david.lewis@ GRO-C
Technical	Name	Dr Pedro <u>Vieira</u> , PhD
Information Manager	Telephone	020 8957 GRO-C office / +44 GRO-C mobile
	Email	pedro.vieira@ GRO-C

Standard Delivery Operating Times	08:00 - 17:00
Delivery Lead Time from Receipt of Order	1-2 working days
Method of Delivery	Alloga MHRA approved chill care provider
Emergency Deliveries Lead Time	3 hours (dependant on delivery point)
Emergency Method of Delivery	BPL own transport or MHRA approved chill courier
Cost of Emergency Deliveries	Quote provided at the time, cost based on various factors i.e. out of working hours



Appendix 3 – Biotest (UK) Ltd

Correct address for	Sales Order Contact	Maxine Gumley
purchase orders	2nd Line Address	First Floor, Park Point
	3rd Line Address	17, High St, Birmingham
	Postcode	B31 2UQ
	Telephone	0121 733 3393
	Fax	0121 733 3066
	Email	sales@biotest.com
Accounts Contact	Name	Wayne Mullins
	Telephone	GRO-C
	Email	wayne.mullins@ GRO-C
Sales Director	Name	Patricia Morey
Contact	Telephone	GRO-C
	Email	patricia.morey@ GRO-C
Technical	Name	Peter Griffiths
Information Manger	Telephone	GRO-C
	Email	peter.griffiths@ GRO-C

19	7/8
Standard Delivery Operating Times	Delivery of orders is possible 24/7. 365 days/year Notification of routine delivery schedules for Christmas and Easter is always communicated one month prior to the holiday period. This information is also available via the company website.
Delivery Lead Time from Receipt of Order	If the orders are placed before 3pm the delivery will be on the next working day. If it is after 3pm it will be delivered in 2 working days. Emergency deliveries are also possible 24/7 365 days.
Method of Delivery	Temperature controlled vehicles.
Emergency Deliveries Lead Time (days)	Depending on the location the delivery can be on the same day.
Emergency Method of Delivery	By road in validated isothermal containers.
Cost of Emergency Deliveries	£1 per mile from the Warehouse (Doncaster) till the delivery point.



Appendix 4 – CSL Behring UK Ltd

Address for	Sales Order Contact	Barbara Kemp
purchase orders	1st Line Address	4 Milton Road
	2nd Line Address	Haywards Heath, West Sussex
	Postcode	RH16 1AH
	Telephone	01444 447400
	Fax	01444 447403
	Email	barbara.kemp@ GRO-C
Accounts Contact	Name	Mike Perry
	Telephone	GRO-C
	Email	Michael.perry@ GRO-C
Sales Director	Name	Steve Allan
Contact	Telephone	GRO-C
	Email	stephen.allan@ GRO-C
Technical	Name	Medical Information
Information Manager	Telephone	01444 447405
	Email	medinfo@cslbering.com

Standard Delivery Operating Times	09:00 - 17:00 Mon-Fri
Delivery Lead Time from Receipt of Order	2 days
Method of Delivery	Overnight Temperature controlled and monitored delivery by truck
Emergency Deliveries Lead Time	Picking & packing time (1-2h) plus travel time from warehouse to delivery point
Emergency Method of Delivery	Direct courier to delivery point in temperature controlled passive packaging
Cost of Emergency Deliveries	Costs dependent on distance from warehouse, calculation based on Mileage and time. Minimum for Emergency delivery is £75 + VAT



Appendix 5 - Grifols UK Ltd

Address for	Sales Order Contact	Alun Evans
purchase orders	1st Line Address	Byron House
	2nd Line Address	Cambridge Business Park, Cambridge
	Postcode	CB4 0WZ
	Telephone	01223 395700
	Email	customer.services.uk@grifols.com
Accounts Contact	Name	Fiona Gilbert
	Telephone	GRO-C
	Email	fiona.gilbert@ GRO-C
Sales Director	Name	Jeannette Storey
Contact	Telephone	GRO-C
	Email	jeannette.storey@ GRO-C
Technical	Name	Ruth Clark
Information Manager	Telephone	GRO-C
	Email	ruth.clark@ GRO-C

Standard Delivery Operating Times	08:00-17:00
Delivery Lead Time from Receipt of Order	1 day
Method of Delivery	Temperature controlled courier
Emergency Deliveries Lead Time	Within 24 hours
Emergency Method of Delivery	Temperature Controlled Courier
Cost of Emergency Deliveries	Courier cost passed on

Supplementary Information:







Appendix 6 – LFB BIOMEDICAMENTS

Address for	Sales Order Contact	Alloga UK Limited
purchase orders	1st Line Address	Amber Park
	2nd Line Address	Berristow Lane, South Normanton, Derbyshire
	Postcode	DE55 2FH
	Telephone	01773 510123
	Fax	01773 810644
	Email	allogauk.orders@alloga.co.uk
Accounts Contact	Name	Sheena Davies / Dawn Butterworth-Smith
	Telephone	GRO-C / GRO-C
	Email	sheena.davies@ GRO-C / dawn.butterworth-
		smith@ GRO-C
Sales Director	Name	Jane Shepard
Contact	Telephone	GRO-C
	Email	shepardj@ GRO-C
Technical	Name	Jane Shepard
Information Manager	Telephone	GRO-C
	Email	shepardj@ GRO-C

Standard Delivery Operating Times	Standard delivery is offered via our logistics partner, Alloga,
	Monday to Friday 08.00 - 18.00 for hospital deliveries.
	Outside these hours an emergency delivery service is in
	place. Standard deliveries are provided free of charge.
	Orders may be placed by phone, email, fax or EDI
Delivery Lead Time from Receipt of Order	For hospital deliveries, order day 1 prior to 16.00 for delivery
	day 2
Method of Delivery	Alloga multi-temperature van fleet (or third party parcel
	carrier in passive packaging for refrigerated product)
Emergency Deliveries Lead Time	A same day service is offered, along with an 'out of hours'
	process
Emergency Method of Delivery	Same day third party carrier (Notts City Couriers); Ambient
	transport will require passive packaging on Urgent basis
Cost of Emergency Deliveries	£1.20 per mile

Supplementary Information:





Appendix 7 - Novo Nordisk Limited

Address for	Sales Order	Luke Spence		
purchase orders	Contact	·		
	1st Line Address	Alloga UK		
	2nd Line Address	AP5, Castlewood Business Park, Farmwell Lane, South		
		Normanton, Derbyshire		
	Postcode	NG17 1JF		
	Telephone	GRO-C		
	Fax	GRO-C		
	Email	Luke.spence@ GRO-C / allogauk.orders@alloga.co.uk		
Finance Contact	Name	Laura Jones		
	Telephone	01773 441688, Ext GRO-C / GRO-C		
	Email	Laura.Jones@ GRO-C		
Sales Director	Name	Sanjay Verghese		
Contact	Telephone	GRO-C		
	Email	save@novonordisk.com		
Technical	Name	Ryan Young GRO-C		
Information Manager	Telephone			
	Email	ryay@ GRO-C		

Standard Delivery Operating Times	Monday to Friday: 08:00 - 17:30
Delivery Lead Time from Receipt of Order	Within 2 Days. Day 1 order for Day 3 delivery
Method of Delivery	To Hospitals: Temperature controlled vehicle from Alloga directly to the Hospital To Patients: via NHS contracted Homecare provider(s)
Emergency Deliveries Lead Time	4 hours
Emergency Method of Delivery	To Hospitals: Temperature controlled vehicle from Alloga directly to the Hospital To Patients: Via NHS contracted Homecare provider(s), in line with specifications of that contract if applicable
Cost of Emergency Deliveries	No cost

Supplementary Information:



BioPharm_Haemophili a_Tender_Supporting



005-NovoSeven_SmP C_UK_v12_Dec_2016._|



Appendix 8 – Octapharma Ltd

Sales order	Name	Tracey Snelson
contact and	1st Line Address	The Zenith Building
address for	2nd Line Address	26 Spring Gardens, Manchester
purchase orders	Postcode	M2 1AB
	Telephone	GRO-C
	Fax	GRO-C
	Email	customer.services@octapharma.co.uk
Accounts Contact	Name	Jane Yarwood
	Telephone	GRO-C
	Email	finance@octapharma.co.uk
Sales and	Name	Clare Worden
Marketing Contact	Telephone	GRO-C
	Email	clare.worden@ GRO-C
Technical and	Name	Kinjal Patel
Medical	Telephone	GRO-C
Information		\
Contact		
	Email	medical.information@octapharma.co.uk

Standard Delivery Operating Times	All orders received Monday to Friday before 15.00 are delivered the next working day before 17.00. Orders received after 15:00 on Friday are processed on Monday for Tuesday delivery. With regard to ordering OctaplasLG; any order received after 15.00 on a Thursday will be delivered the following Tuesday before 17.00, as OctaplasLG is a frozen product.
Delivery Lead Time from Receipt of Order	One working day. Please see note above regarding orders received after 15.00 on a Thursday
Method of Delivery	Couriered by Alloga UK
Emergency Deliveries Lead Time	Same day deliveries are available - orders are despatched immediately upon receipt and will be charged dependant on location. Travel time is dependent on the distance from the Alloga UK warehouse in South Normanton, Derbyshire
Emergency Method of Delivery	Couriered by Alloga UK Limited
Cost of Emergency Deliveries	The cost is dependent upon the hospital location. When an urgent order is received, we request a price from Alloga UK Limited and this would be agreed with the trust prior to order despatch



Appendix 9 - Roche Products Ltd

Address for purchase	Name	Customer Care
orders	1st Line Address	6 Falcon way
	2nd Line Address	Shire Park
	3rd Line Address	Welwyn Garden City, Herts
	Postcode	AL7 1TW
	Telephone	0800 731 5711
	Fax	0800 169 5432
	Email	welwyn.orders@roche.com
Accounts Contact	Name	Credit Control
	Telephone	
	Email	welwyn.credit_control@roche.com
Sales Director	Name	On Request
	Telephone	
	Email	
Technical Information	Name	Med Info
Manager	Telephone	0800 3281629
	Email	medinfo.uk@roche.com

Standard Delivery Operating Times	UK Logistics Provider (Alloga) standard delivery times are between 08:00 and 17:00 Mon-Fri
	NI Logistics Provider (Movianto) standard delivery times are between 08:00 and 17:00 Mon-Fri
	Roche customer care opening hours are 08:30-17:00 Mon-Fri
Delivery Lead Time from Receipt of Order	Usually next working day, however will depend on geographical location. Usually 1-3 working days
Method of Delivery	Generally via contracted logistics provider Alloga, or one of their approved subcontractors (England, Wales and Scotland).
	NI deliveries will be made via Movianto NI.
Emergency Deliveries Lead Time (hours)	See Below
Emergency Method of Delivery	Although Emergency delivery is unlikely to be required for the submitted product, a same day delivery is offered via courier (location dependant)
Cost of Emergency Deliveries	Cost is location dependant



Appendix 10 - Shire Pharmaceuticals Ltd

Address for purchase	1st Line Address	1 Kingdom Street
orders	2nd Line Address	London
	3rd Line Address	
	Postcode	W2 6BD
	Telephone	0800 358 0952
	Email	servicecCS.UK@shire.com
Accounts Contact	Name	Nick Insall
	Telephone	GRO-C
	Email	nick.insall@ GRO-C
Sales Director	Name	Alan Walshe
	Telephone	GRO-C
	Email	alan.walshe@ GRO-C
Technical Information	Name	Shire Pharmaceuticals Ltd
Manager	Telephone	0800 055 6614
	Email	medinfoEMEA@shire.com

Standard Delivery Operating Times	Normal working hours are classified as Not relevant		
Delivery Lead Time from Receipt of Order	Not relevant		
	Not relevant		
	Not relevant	ļ	
	Not relevant		
Method of Delivery	All products supplied under this contract require cold chain delivery and would be delivered to the participating authorities using appropriate technology to maintain cold chain requirements.		
Emergency Deliveries Lead Not relevant	Not relevant		
Emergency Method of Delivery	Not relevant		
	Not relevant		
Cost of Emergency Deliveries	Not relevant Not relevant		

